About Managing Director

Jeannie Kim, BSc, MEM, MBA

Brings over 20 years of Life Science global corporate development and strategy leadership in enterprise transformations (ie. growth initiatives/turn-arounds) and building critical mass for pioneering and emerging technologies through strategy, portfolio prioritization, and strategic partnership ecosystems, as a consultant, advisor, and fractional executive (CBO/CBDO/COO/Strategy/Marketing).

With a comprehensive background across traditional pharmaceuticals/biotech, med tech/techbio, and medical devices, she specializes in innovations that leverage their synergies and intersections to advance personalized medicine and/or improve access.

[eg. companion diagnostics (sequencing to POC in global health), molecular imaging/radioligands, robotic radioguided surgery/imaging (radiopharmaceutical-based surgical guidance), digital health applications for decentralized trials (interoperability), AI applications in discovery/translational research to health system care delivery.]

Originally trained as an engineer, she began her career designing surgical instruments & dialysis devices for Baxter International and values creativity in both engagement and data-driven strategies over cookie-cutter approaches for novel scientific/technological innovations.

Her corporate development background began on the buy-side with multinationals (Pharmacia/Pfizer, Philips Medical). Her first out-license/sell-side deal assignment to secure a collaboration investment partner for a drug-device program struggled with limited to no external interest for over 2 years, earmarked for liquidation. In a little over a year, by restructuring the program’s partnering strategy and translating its value narrative for targets’ commercial relevance, it ultimately became a multinational partnership with a subsequent platform acquisition, collectively valued up to $300 million.

Since then, Ms. Kim has successfully closed over 50 transactions, >$5B in aggregate across (in/out) licensing, equity, and M&A -- in rare/orphan diseases, neurology/ophthalmology, metabolic disorders, aging/longevity, oncology, immunology, women’s health, and infectious disease.

She’s partnered with leadership in collaboration with small pioneering teams across multinationals, non-profits, and start-ups, seeking to move the needle in healthcare along the continuum from enterprise strategy, portfolio and workflow optimization to transactions and alliance management.

Previously, she held global corporate business development & strategy leadership roles and engagements with multinationals from Pfizer/Pharmacia/GD Searle (US, UK, MENEA), Johnson& Johnson, Philips Medical Systems, Pulmonary Unit of Nektar (now Novartis), Thermo Fisher Scientific – Clinical Sequencing, Biogen, GSK plc, including global health public-private partnerships with PATH/GSK/Gates Foundation and Medicines360. She believes in compassionate leadership and enjoys leveraging her experience to drive growth for inspiring innovations, organizations, and people.

Ms.Kim holds a BSc in Biomedical/Mechanical Engineering, joint degree in Masters in Engineering Management and Masters in Business Administration from Northwestern University and Northwestern’s Kellogg School of Management, respectively. JD studies in Business Law/Animal (Environmental) Law at Lewis & Clark Northwestern School of Law. Stanford Medicine certification in Evaluations of AI applications in Healthcare.

Based in the San Francisco Bay Area with a presence in Portland, Oregon, Jeannie works with life science organizations across the country — remotely and on-site.

Member of Northwestern’s Alumni Admissions Council. Global Advisory - Women in STEM Network, Kellogg Women's Forum, with strong interest in the arts, animal welfare, wildlife conservation, and poverty alleviation.